改进计划总是改善那些从来不是约束点的地方，因为那里最容易改进。 数字健康公司面临特定困境——结果风险承诺速度快于公司验证自身能否承担的节奏，12个月测量窗口对上11个月销售周期。若不解决定价问题，按风险分成收入将继续无从归因地变动，而关于约束点吞吐量的讨论仍停留在主观意见。
改进计划总是改善那些从来不是约束点的地方，因为那里最容易改进。 数字健康公司面临特定困境——结果风险承诺速度快于公司验证自身能否承担的节奏，12个月测量窗口对上11个月销售周期。若不解决定价问题，按风险分成收入将继续无从归因地变动，而关于约束点吞吐量的讨论仍停留在主观意见。
每家数字健康运营在任意时刻都有一件事限制已归因结果——12个月测量窗口、按风险分成验证参与率的能力，或必须支持PMPM经济的团队。在其他地方做的工作不会增加通过窗口的收入，只会增加已入组但结果尚未确认的成员数量。这点四十年来早已明确，却仍被改进计划反复违反，结构性原因是：举措由主动提出的团队生成，而受限团队因新风险合同签订而本无余力提出。
结果是项目卫生出色却无效果。参与仪表盘得到优化，标准流程写成文档，可见看板追踪成员活动，但测量窗口后转化的收入份额不变。由于活动真实，毛利率持平的应对通常是更多举措，这消耗了本不限制风险分成转化的团队产能。
这类项目中隐藏的第二件事是约束点常充满错误工作。账簿以合同满负荷运行，而这些合同的归因结果不产生收入，这不是效率问题，而是披着效率外衣的选择问题。方法无法修复，方法应用只会让无利可图的风险分成更易管理，从而增加其数量。
效率转型策略（目录编号T12）从约束点及其占用内容出发——稀缺测量窗口内验证结果的吞吐量、风险分成的单位贡献，以及下一份合同在窗口关闭后支付所需的条件。若答案是流程本身确为限制，则精益项目是正确选择，分析将指出瞄准位置。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 参与率上升，但客户流失和通过测量窗口的风险收入份额保持不变
✓ 无人能单独指出哪一步决定已归因结果能否在下一份合同签订前通过12个月窗口
✓ 改进最显著的团队，其工作从未触及决定风险账簿毛利率的结果验证
通常会让情况更糟的做法。 在整个运营中 rollout 方法，将稀缺改进产能消耗在从未限制风险分成转化的步骤上。
It is for you if you run or finance a digital health company and a large number of completed improvement initiatives and unchanged output. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Customer Value Architecture · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 效率转型策略, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
两者解决不同问题，选择重要性低于目标。精益针对流程和等待；六西格玛针对变异和缺陷。若问题是事物滞留队列，选精益。若是输出不一致，选六西格玛。若尚不清楚，方法选择为时过早，任一都会产生活动。
评估阶段大致£40k–£120k。完整部署含嵌入从业者和培训，通常一年£250k–£1m，常按承诺节省倍数报价。需询问基线如何设定、由谁验证节省，因为自证效益是常态且系统性偏高。
方法可以——材料公开且低价，许多公司自学成功。真正难以自供的是外部判断：该瞄准何处，以及愿意指出受青睐部门并非问题所在。这部分值得购买，且远小于完整部署的费用。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית